This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/helping-new-cells-survive-how-tiny-drug-carriers-may-support-future-vision-repair-in-glaucoma

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Helping New Cells Survive: How Tiny Drug Carriers May Support Future Vision Repair in GlaucomaGlaucoma is a leading cause of permanent blindness worldwide. In glaucoma, a type of nerve cell in the eye called a retinal ganglion cell (RGC) gradually dies, leading to loss of vision () (). These cells normally carry visual information from the eye to the brain, so when they go, peripheral vision fades and darkness creeps in. Today’s treatments for glaucoma focus on lowering eye pressure (for example with eye drops) to slow damage, but they cannot bring back lost RGCs or recover eyesight () (). Researchers are exploring new ways to one day fix this problem by replacing or protecting those lost nerve cells. One exciting idea is to transplant healthy RGCs (grown from stem cells) into the eye. In principle, these new cells could reconnect the retina to the brain. But there’s a catch: simply planting new cells into a diseased eye is not enough. New transplanted RGCs often do not survive very long. In experiments, many new cells were found trapped in the eye’s fluid without the support they need, and they quickly died (). Because of this, scientists are looking for tricks to help the transplanted cells live and grow.What scientists are trying to fixThe goal is to fix the damage that glaucoma causes – namely, the loss of RGCs that carry vision signals. Since human RGCs cannot simply regenerate on their own, one approach is to replace them. Scientists can create RGC-like cells from stem cells and transplant them into the retina (). Another goal is to protect the remaining RGCs from dying in the first place, to save patients’ vision.However, both strategies face big challenges. Any new RGCs (either transplanted or surviving ones) must grow axons (“wires” of the cell that carry signals) all the way to the brain. They need a friendly environment (with nutrients and supporting signals) to survive. The eye tissue in glaucoma is often stressed by high pressure and inflammation, which makes it a harsh place. For example, transplanted cells in rodent eyes were found mostly stuck in the eye fluid (the vitreous) where they lacked life–support signals (). As a result, most died soon after transplant. This low survival rate means simply adding new cells “is not enough to compensate for what glaucomatous retina needs to see again” – it remains an unsolved problem () ().What do scientists want to fix? In short, they want to replace or rejuvenate the lost RGCs and restore the optic nerve pathway. This could mean transplanting healthy RGCs (from embryonic or induced stem cells) and helping them integrate, or finding ways to rescue the patient’s own remaining cells with drugs or other therapy. But so far, no method in the clinic can truly restore the lost cells or reconnection in glaucoma (). That’s why researchers are looking at creative new tools – including nanomedicine – to give these transplanted cells a fighting chance.Why simply adding new cells may not be enoughPicture a garden bed (the retina) where plants (RGCs) have died out. You might think replanting new seedlings should work, but if the soil is poor and the climate harsh, the new plants won’t thrive. The same goes for

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/could-cell-transplants-one-day-restore-vision-in-glaucoma-a-new-study-looks-at-one-major-roadblock

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Could Cell Transplants One Day Restore Vision in Glaucoma? A New Study Looks at One Major RoadblockGlaucoma is a leading cause of permanent blindness. In glaucoma, retinal ganglion cells (RGCs) die off over time. These RGCs are special nerve cells in the eye that receive signals from light-detecting cells and carry them through the optic nerve to the brain () (). When these ganglion cells are lost, the visual signals can’t reach the brain, and vision is irreversibly damaged. Unfortunately, adult eyes cannot naturally regrow these lost nerve cells, so once vision is gone it’s gone for good () (). Scientists have long dreamed of replacing lost RGCs by transplanting new cells into the retina. If new ganglion cells could be made to survive and connect correctly, they might restore vision in people with advanced glaucoma. A promising source of new cells is stem cells – for example, skin or blood cells from a patient can be reprogrammed into stem cells, and then coaxed in the lab to become new RGCs. In fact, researchers note that developing lab-grown RGCs “holds the potential to some day make possible the restoration of vision” for people who have lost it (). However, this goal has always faced very big challenges. Retinal Ganglion Cells and GlaucomaRetinal ganglion cells are essentially the final output cells of the retina. They collect and bundle up visual information from the retina’s photoreceptors and interneurons, then send that information along their long axons through the optic nerve to the brain (). You can think of them as the retina’s wiring that plugs into the brain. In glaucoma, pressure or other damage causes these RGCs to slowly die off. A medical review explains that glaucoma is “characterized by selective, progressive degeneration of the retinal ganglion cells” – in other words, these cells gradually disappear over time (). Once that happens, the eye cannot send visual signals anymore and vision is lost. Importantly, mammalian RGCs do not regenerate on their own. ()Because of this, current glaucoma treatments can only slow vision loss (for example, by lowering eye pressure) – they cannot restore the lost RGC cells or recover vision that has already been lost. That is why researchers are pursuing cell replacement: the idea is to transplant healthy new RGCs into the retina to replace the dead ones. But as scientists explain, the retina of adults is not easily re-wired, which makes this very difficult.Why Replacing These Cells Is So HardTransplanting RGCs into a retina and having them work properly faces many hurdles. One big obstacle is the structure of the eye itself. The innermost surface of the retina (next to the vitreous gel inside the eye) is covered by a thin layer called the inner limiting membrane (ILM). The ILM is essentially a basement membrane that separates the retina from the eye’s interior. In simple terms, it is like a transparent inner lining on the surface of the retina (). This membrane (while important during eye development) becomes a physical barrier in the adult eye. Experts have noted that the ILM “may constitute a significant barrier to emerging ocular therapies” like gene therapy or cell transplants (). In fact, a recent r

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-implant-study-can-it-protect-vision-and-can-it-bring-lost-vision-back

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Glaucoma Implant Study: Can It Protect Vision, and Can It Bring Lost Vision Back?Glaucoma is a common eye disease that slowly damages the optic nerve (the bundle of nerve fibers that carry visual signals from the eye to the brain), leading to irreversible vision loss (). Most current glaucoma treatments work by lowering the fluid pressure inside the eye. However, even when pressure is controlled, some patients still lose vision over time. Doctors describe this damage as a neurodegenerative process – the nerve cells in the eye’s retina (called retinal ganglion cells) are dying off. Right now, no approved treatments directly protect those nerve cells (). That’s why researchers are excited about a new experimental implant called NT-501 (also known as Encelto). This tiny device continuously releases a nerve-growth protein (ciliary neurotrophic factor, or CNTF) inside the eye, with the goal of neuroprotection – preserving the remaining vision by keeping the retinal nerve cells alive and healthy.What is the NT-501 (Encelto) CNTF implant?The NT-501 implant is a small capsule (about 1×6 mm) that a surgeon places inside the eye (in the gel-like vitreous near the retina) during a minor procedure () (). Inside the capsule are living cells that have been genetically engineered to produce human CNTF, a protein that acts like a “fertilizer” for nerve cells. CNTF belongs to a family of growth factors known to help retinal neurons survive and grow (). Over many months (up to a couple of years), the implant slowly pumps CNTF into the eye. In effect, the implant is like a tiny medicine-pump that continuously bathes the nerve cells in protective growth factor () (). Neurotech Pharmaceuticals (the maker) calls this encapsulated cell therapy Encelto. Notably, the same implant was FDA-approved in 2025 for a different eye disease (macular telangiectasia type 2) (), which shows it can be safely placed in the eye. For glaucoma, doctors hope the constant light dose of CNTF will protect the retinal nerve cells from the stress of glaucoma. What does “neuroprotection” mean?“Neuroprotection” literally means protecting nerve cells. In glaucoma, neuroprotection refers to any treatment that slows or stops the death of the retinal nerve cells, helping to preserve the patient’s existing vision. To explain it simply: if an eye drops from seeing 20/40 to 20/70 every year without treatment, a neuroprotective therapy might slow that decline so the patient stays closer to 20/40 for much longer. In a recent article, Dr. Jeffrey Goldberg (the glaucoma researcher leading these studies) noted that maintaining vision by stopping degeneration is exactly what neuroprotection is meant to do (). (He contrasts this with improving vision beyond the original level – which he called “neuroenhancement” – a higher bar that would mean actually recovering lost vision ().) In short, a neuroprotective treatment protects what you already see, slowing further loss.What did the studies find so far?Early (Phase I) results – small safety trialResearchers first tested this implant in a small safety study. In that Phase I trial, 11 patients with open-angle glaucoma were enrolled (). Each patient had one eye receive the NT-501 implant

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/what-is-a-24-2-visual-field-test

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

What Is the 24-2 Visual Field Test?Visual field testing is a key way to measure what you can see in your peripheral (side) vision as well as centrally. The 24-2 test is a specific type of automated visual field exam used in glaucoma care. In simple terms, during a 24-2 test you will sit at a machine (often a Humphrey Field Analyzer) and look straight ahead at a fixed target. Small lights (called stimuli) will flash at various spots in your field of vision. You press a button every time you see a light. The machine records which points you see and which you miss. This builds a map of your visual field, showing areas of normal vision and any blind spots or sensitivities you may have. Because glaucoma damages specific nerve fiber layers in the retina, the 24-2 pattern is designed to catch the most common glaucoma defects (like curved “arcuate” blind spots, paracentral loss, and nasal steps) efficiently across your central 24 degrees of vision () (). It is the single most widely used standard field test in glaucoma evaluation worldwide.The Meaning of “24-2” The name “24-2” comes from the visual field area and pattern spacing it covers. The “24” means the test covers the central 24 degrees of your vision in all directions (roughly a 24° radius from the point you stare at). This includes your central vision and some surrounding peripheral vision, but it stops short of the far edges. The “–2” is a technical detail from the naming convention: it basically means that no test points lie exactly on the vertical or horizontal axes – points are offset by 2 degrees from those lines. The practical takeaway is that the test focuses on a central square region (±24°) around where you fixate, with test points in a grid pattern at 6° intervals () (). In practice, you don’t need to worry about the exact meaning of “–2” – just know that 24-2 is a standard pattern and your doctor will always compare like-to-like when tracking changes.How the 24-2 Grid Is DesignedThe 24-2 test uses a grid of 54 test points spread across your central vision. These points are arranged roughly 6 degrees apart (imagine an 8-by-7 grid) (). Figure out that spacing: if you connect four nearby points in a square, there’s about a 3° gap (radius) in the center where the machine does not test. This design was chosen as a compromise between coverage and speed: more points would catch more detail but make the test much longer and more tiring. By keeping the points 6° apart, a 24-2 test typically finishes in about 5 minutes or less per eye on SITA Standard mode (), which is manageable for most patients (even older adults). Importantly, the pattern is tailored for glaucoma. It retains a couple of extra points on the nasal (inner) side of vision specifically to detect the classic “nasal step” defect of glaucoma (). It also covers both the upper and lower arcs of vision coming out of the blind spot, where glaucoma often causes arcuate (arc-shaped) scotomas. In other words, the 24-2 grid probes the areas of retina that send signals to the optic nerve in a way that tends to be damaged first by glaucoma. In fact, large studies have shown that when glaucoma does progress, it most often harms the nasal and paracentral regions of the 24-2 field (). By covering those zones plus the surrounding retina, the 24-2 test maximizes the chance of catching typical

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/how-fast-does-glaucoma-progress

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

How Fast Does Glaucoma Progress?Glaucoma is not a one-size-fits-all disease – its course varies dramatically from person to person. Some patients’ vision barely changes over decades, while others may slide from mild damage to legal blindness in just a few years, even with treatment. Knowing your place on this spectrum is crucial. It indicates how aggressively your doctor should treat you, how often you need check-ups, and ultimately whether you’ll keep useful vision for life or risk losing it. In short, the speed of your glaucoma’s progression is the single most important piece of information in your care. This article reviews the hard data on glaucoma progression rates from major clinical studies and explains what factors influence individual risk, how doctors measure worsening, and what patients can do to slow the clock.Spectrum of Glaucoma Progression RatesThere is no single answer to “how fast does glaucoma progress?” – rates vary enormously. Major studies show untreated glaucoma often worsens substantially over years. For example, in the Early Manifest Glaucoma Treatment (EMGT) trial (newly diagnosed open-angle glaucoma), untreated patients’ visual fields declined at a median of –1.0 to –2.0 dB per year in mean deviation (MD) (). Roughly 60% of untreated patients met clear “definite progression” criteria within six years (). When treated with pressure-lowering drops or laser, progression slowed but did not stop. In EMGT, treated eyes lost only about –0.5 dB/year on average, and only ~45% progressed in six years (). Large clinical cohorts confirm huge variability. A Swedish practice survey found the mean perimetric decline was –0.80 dB/year (median –0.62 dB/year), but the range was broad – about 5.6% of patients lost more than –2.5 dB/year (). In practical terms, even a “small” loss of –0.5 dB/year (half a tenth of normal visual sensitivity per year) adds up relentlessly over decades. For instance, a patient diagnosed at age 50 with a mild mean deviation of –3 dB could reach –18 dB (moderate-to-severe loss) by age 80 at –0.5 dB/yr. Conversely, someone losing –2.0 dB/year (a fast rate) without treatment might hit –18 dB in only seven or eight years – a devastating slide.The Canadian Glaucoma Study (a large natural history series) likewise found that treated glaucoma often changes slowly on average, but with a long “tail” of fast progressors. The overall mean MD decline in treated patients was only about –0.05 dB/year, but the distribution was wide. In fact, the fastest 20% of patients in that study were losing more than –1.5 dB/year despite therapy. These findings underscore that truly answering “how fast is my glaucoma progressing?” requires personal data: individual trajectories vary far more than averages () ().What Do Published Studies Tell Us?Several landmark trials have quantified glaucoma progression rates in untreated and treated eyes. Understanding their findings grounds our understanding of “fast” vs. “slow” disease:Early Manifest Glaucoma Treatment (EMGT) – In this trial of newly diagnosed open-angle glaucoma patients, untreated control eyes had a median MD decline around –1.0 to –2.0 dB/year, and about 60% showed definite glaucoma progression within six years (). Eyes treated with pressure-lowering (initially betaxolol drops plus laser) declined about half as fast

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/perioperative-pitfalls-supplements-that-raise-bleeding-risk-in-glaucoma-surgery

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Perioperative Pitfalls: Supplements That Raise Bleeding Risk in Glaucoma SurgeryGlaucoma surgery, such as trabeculectomy or tube shunt procedures, requires careful blood clotting to heal properly. Many patients take over-the-counter herbal or dietary supplements for general health or eye health. Some of these supplements – including things like ginkgo biloba, garlic, ginseng, fish oil (omega-3), high-dose vitamin E, and turmeric/curcumin – can “thin the blood”. In other words, they make it harder for blood to clot after an injury. During eye surgery, even a small bleed can lead to serious complications or vision loss. This article reviews which common supplements have blood-thinning effects, what the evidence says about their bleeding risk, how long before surgery they should be stopped, and how doctors can talk to patients about supplement use. We also provide a sample checklist for preoperative visits to make sure supplements are not overlooked.Supplements That Can Thin the BloodMany nutritional supplements and herbal remedies affect blood clotting. Below we describe key supplements known to interfere with platelets or clotting factors, and summarize the evidence about bleeding risk from studies or case reports.Ginkgo BilobaGinkgo biloba is an herbal memory aid that can affect clotting by blocking platelet-activating factor (). In lab tests and animal models it shows antiplatelet and antithrombotic effects (). A small clinical trial found that ginkgo reduced platelet clumping, although standard clotting tests stayed normal (). Importantly, several case reports link ginkgo use to bleeding problems. For example, ginkgo has been reported in isolated cases to cause spontaneous eye bleeds (hyphema) or even brain hemorrhages (). A recent analysis also found that taking ginkgo with other blood thinners (like aspirin or clopidogrel) significantly raised bleeding risk (). In short, evidence suggests ginkgo can increase bleeding, especially when combined with other anticoagulants () (). Many surgeons therefore advise stopping ginkgo well before surgery (often 1–2 weeks prior) to allow its effects to wear off.Garlic (Allium sativum)Garlic supplements are popular for heart health, but garlic can thin the blood. Garlic contains sulfur compounds (like allicin and ajoene) that inhibit platelet aggregation in a dose-dependent way (). Even though large trials have been inconsistent about clinically significant bleeding, several case reports document bleeding issues with high garlic intake (). For example, one report showed that a patient on warfarin had dangerously high INR (over-thinning of blood) after taking garlic supplements (). As a result, experts caution that garlic can add to bleeding risk. Many pre-surgery guidelines recommend stopping garlic about 1 week before an operation to avoid potential clotting problems () ().Ginseng (Panax species)Ginseng root (Asian or American) is an “adaptogen” taken for energy or diabetes, but it can also affect clotting. Laboratory studies have found that ginseng extracts can inhibit platelet aggregation and even prolong clotting times in animals (). In practice, however, reports of bleeding from ginseng are rare. Clinical evidence of ginseng causing hemorrhage is weak: only a f

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/does-diabetes-cause-glaucoma

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

IntroductionDiabetes mellitus and glaucoma are two of the most common chronic diseases affecting the eye. At first glance, they can seem quite different. Diabetic retinopathy develops primarily because high blood sugar in diabetes damages the tiny retinal blood vessels. In contrast, primary open-angle glaucoma (POAG), the most common form of glaucoma, traditionally is thought to arise from increased pressure inside the eye (intraocular pressure, or IOP) that slowly injures the optic nerve. Thus it is natural to ask: Does diabetes cause glaucoma in the same clear-cut way it causes diabetic retinopathy? The answer is nuanced. Diabetes does not directly “cause” POAG in the linear, one-to-one way that high blood sugar causes retinal blood vessel damage. Instead, accumulating evidence shows that diabetes significantly increases the risk of developing glaucoma by creating a complex biochemical and vascular environment in the eye that makes glaucoma more likely to start, worsen faster, and respond less well to treatment.Specifically, large epidemiologic studies and meta-analyses have found that people with diabetes carry roughly a 36–50% higher risk of developing POAG than people without diabetes, after accounting for factors like age and race () (). However, this statistical association does not mean that every diabetic patient will get glaucoma, or that diabetes directly injures the optic nerve in the same way it injures blood vessels. Instead, researchers believe multiple overlapping mechanisms are at work. These range from the toxic effects of chronic high blood sugar on the drainage angles of the eye, to insulin-related changes in fluid production, to diabetic nerve damage and inflammation, and to decreased blood supply to the optic nerve. Moreover, diabetes is an undeniable cause of a very severe secondary glaucoma called neovascular glaucoma, which arises from advanced diabetic retinal disease and accounts for a disproportionate share of tragic vision loss in diabetics. In this article we will explore in detail how diabetes influences glaucoma risk and progression. We will begin by reviewing the evidence that diabetes and POAG are linked, then dissect the multiple mechanical and cellular mechanisms by which high blood sugar and related metabolic changes damage the eye’s outflow pathways, optic nerve, and support structures. We will also cover neovascular glaucoma, walking through the classic cascade from advanced diabetic retinopathy to painful, severe glaucoma. We will critically examine the epidemiology – why some studies find strong associations and others do not, and how diabetes is entwined with many other risk factors. We will discuss real-world challenges when both diseases coexist (for example, how diabetic treatments can mimic or mask glaucoma and vice versa). We will then look at treatment considerations for glaucoma in diabetics, from medication interactions to surgical outcomes. Finally, we will survey emerging research at the “frontiers” – how diabetic neurodegeneration, gut microbiome changes, diabetes medications (like metformin and GLP-1 agonists), and genetics may link the two diseases. Throughout, we aim to translate technical insights into practical, patient-friendly guidance. Our goal is to give patients and their doctors an actionable framework: how to screen, prevent, a

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/can-you-have-glaucoma-in-one-eye

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

IntroductionYes – glaucoma can indeed strike one eye while sparing the other, or at least cause one eye to be much worse than its fellow. In fact, it is surprisingly common for glaucoma to present asymmetrically: a large fraction of newly diagnosed patients have one eye with higher pressure, more optic nerve damage, or worse visual field loss than the other. Indeed, even classic forms of glaucoma that are generally bilateral often begin or are detected in one eye first. Clinicians report that roughly one- to two-thirds of patients show significant inter-eye differences in at least one measure at diagnosis. For example, one study found that interocular pressure differences of 3 mmHg or more were highly predictive of glaucoma [64] and other research shows that meaningful visual field or nerve-fiber loss asymmetry can occur in on the order of tens of percent of patients. This asymmetry is clinically important – it both preserves useful vision (since the “good” eye compensates) and masks the disease (because the patient doesn’t notice a problem until very late). In this article we will explore unilateral and asymmetric glaucoma in depth. We begin with why one eye can be affected more than the other, then discuss how the healthy eye hides the loss in the bad eye. We review all known causes of truly one-sided glaucoma (from eye trauma to inflammatory disease to eye structure differences). We explain why one optic nerve might be more vulnerable than the other even under similar eye pressure, and why we sometimes see glaucoma only in one eye in angle-closure disease. We cover how doctors use the two eyes as a pair of internal controls to diagnose and track glaucoma, and what else must be ruled out when damage is very uneven. Finally, we talk about what life is like for a patient with glaucoma in “only one eye,” including the coping, driving, and treatment issues unique to this situation. In each section we will point out relevant studies or clinical observations to back up the discussion () () (). With any luck, you’ll come away with a clear understanding that asymmetric glaucoma is not mild – it’s sneaky, and requires special vigilance in both diagnosis and treatment.How and Why Glaucoma Can Affect One Eye More Than the OtherUnder ideal conditions, glaucoma tends to be a bilateral disease (affecting both eyes) because many risk factors – like blood pressure, genetics, and age – are systemic. However, eyes are not identical twins, and even in the same person there can be meaningful differences between the two eyes. These differences can occur at every level: eye pressure, drainage anatomy, history of injury or disease, and even the susceptibility of the optic nerve. Below we list the main factors that can lead to one eye developing glaucoma (or worse glaucoma) when the other eye is relatively healthy.Inter-eye pressure asymmetry. In most people, the pressures in the right and left eye are similar, but often one eye runs a bit higher. Even a seemingly small difference can matter. Studies show a clear dose–response effect: as the gap in pressure grows, the risk of glaucoma soars. For example, one multicenter study found that when the IOP (intraocular pressure) difference between eyes was 3 mmHg, the chance of having glaucoma rose to about 6%; if one eye was >6 mmHg higher, that risk jumped to ~57% ()

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/zinc-copper-and-optic-neuropathy-when-supplements-mimic-glaucoma-progression

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Introduction Many people take zinc supplements believing they help the immune system or heart health. Too much zinc, however, can upset the balance of copper in the body. In rare cases, high-dose zinc over months or years causes copper deficiency, which damages the optic nerve (the bundle of fibers that carries vision signals from the eye to the brain). The result is vision loss that can look a lot like worsening glaucoma – even when eye pressure is well controlled. This article explains how zinc affects copper, how copper deficiency can hurt your optic nerve, and how that can be mistaken for glaucoma progression. We’ll highlight key clues that the problem is nutritional rather than glaucoma, and suggest safe supplement practices. At the end, a practical checklist is offered to guide doctors when a glaucoma patient’s sight falls off despite normal eye pressure. Zinc, Copper, and the Eye Zinc and copper are essential minerals needed for many body functions, including healthy vision. Both travel through your digestive system and bloodstream, but they compete for absorption. When you take a lot of zinc, it triggers production of a protein (metallothionein) in intestinal cells that grabs copper and holds it in the gut, so less copper enters your body (). In effect, excess zinc “starves” your body of copper. Over time, this can lead to low blood copper (hypocupremia). Copper is crucial for nerve health. In particular, it helps maintain the myelin sheath around nerves and is part of important enzymes. Copper deficiency can cause many neurologic problems – for example, numb hands and legs, trouble walking, and optic neuropathy (damage to the optic nerve) () (). Recognizing this is important because copper-related optic nerve damage can be treated. In fact, cases have been reported of patients who were legally blind (20/400 vision) partly regain good sight (to 20/25) after getting copper supplements (). It’s worth noting that many people regularly exceed safe zinc intakes. The National Institutes of Health advise that healthy adults only need about 8–11 mg of zinc per day, and the safe upper limit is 40 mg/day (). Yet some immune boosters, eye health formulas, and multivitamins provide 25–80 mg of zinc daily without increased copper. A survey found about 5–8% of U.S. adults taking zinc supplements exceed that 40 mg limit (). Without extra copper, long-term high zinc use can therefore create copper deficiency – so doctors should be aware of this hidden risk () (). Copper Deficiency Optic Neuropathy: Symptoms and Signs When the optic nerve is damaged by copper deficiency, vision loss usually comes on slowly and in both eyes at once. Patients often note that colors look faded and that there is a dark spot or patch in their center of vision (). One review explains that nutritional optic neuropathies typically cause a central (cee-cocentral) scotoma – a blind spot that affects the central field, with the far side vision remaining mostly fine (). In other words, side vision tends to be preserved while central sight (reading, recognizing faces) is hurt. Because both eyes are affected similarly, there usually is no relative afferent pupillary defect (RAPD) – the doctors’ test where shining light into one dark ey

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/how-long-does-a-glaucoma-test-take

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

How Long Does a Glaucoma Test TakeVisiting the eye doctor to check for glaucoma can feel overwhelming – not least because there isn’t a single “glaucoma test” but a whole battery of exams. Depending on whether you’re just getting a routine screening, a full diagnostic workup, or follow-up for known glaucoma, your doctor will pick some or all of the following tests. Understanding what each test involves – and how long it actually takes – can remove the mystery. It can help you schedule the right amount of time, arrange a ride home if your eyes will be dilated, and plan breaks so you stay comfortable instead of stressed. In short, knowing the timing for each step means you won’t be rushed or confused during what may be one of the most important appointments of your year. Below we break down each common glaucoma-related test, roughly how long it takes, and why it matters. We then explain how these pieces add up to real-world exam lengths – from a quick pressure check to a full, two-hour glaucoma workup. Finally, we offer practical tips for your visit and set realistic expectations by visit type, stage of disease, and purpose of the exam. Remember: taking these tests seriously and sparing time for them is vital for catching any glaucoma damage early and protecting your vision. Why There Is No Single Glaucoma TestFirst, let’s be clear: glaucoma isn’t diagnosed by one magic test or machine. Instead, ophthalmologists and optometrists put together information from several exams. For example, one person’s glaucoma checkup might include only an eye pressure test and a quick look at the optic nerve during a routine eye exam. But a patient with suspected glaucoma or confirmed disease will get many more tests (like a full visual field test, imaging scans, nerve photos, etc.). Each test gives a different piece of the puzzle. Some measure intraocular pressure (IOP), others measure corneal thickness, the drainage angle of the eye, the thickness of optic nerve fibers, or functional vision in the peripheral field. No single test alone can diagnose most cases of glaucoma. In fact, experts agree that combining multiple tests is essential for accurate screening and diagnosis () (). Knowing this helps you understand why an appointment might feel long: your eye doctor needs a full picture of eye health before concluding whether glaucoma is present or progressing. Below are the most common components of a glaucoma evaluation, listed roughly in the order they might happen (technicians often screen before you see the doctor). We note the approximate time each step takes, so you can see how minutes add up and why a thorough exam can stretch to an hour or more.Eye Pressure Measurement: Tonometry (1–3 seconds per eye)Tonometry measures the pressure inside your eyes, an important factor in glaucoma. There are two common methods:Goldmann applanation tonometry (GAT) uses a tiny blue light and a small probe touching the surface of the eye. You’ll get an anesthetic drop, and then the doctor or technician will align a slit-lamp (microscope) to gently touch a calibrated tip to your cornea. The actual pressure reading in each eye takes only about 1–2 seconds once set up, though positioning the instrument can take a minute or two per eye. Non-contact (air-puff) tonometry uses a quick puff of air. You sit at a machine a

Support the show